NCT03326973View on ClinicalTrials.gov

Long-Term Quality of Life in Patients With Metastatic Melanoma Treated With Checkpoint Inhibitors

CompletedOBSERVATIONAL
Enrollment

107

Participants

Timeline

Start Date

October 25, 2017

Primary Completion Date

December 14, 2020

Study Completion Date

December 14, 2020

Conditions
Metastatic Melanoma
Interventions
BEHAVIORAL

EuroQoL EQ-5D-3L

Overall QOL

BEHAVIORAL

EORTC QLQ-C30

General symptoms; physical, role, emotional, cognitive, and social functioning scales; fatigue, nausea/vomiting , and pain scales

OTHER

PRO-CTCAE

Additional potential immune-specific symptoms

BEHAVIORAL

Fatigue severity score questionnaire

Fatigue severity

BEHAVIORAL

The COST

Financial toxicity; satisfaction with ability to work

BEHAVIORAL

Physician information

Details on outside health providers

Trial Locations (6)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11570

Memorial Sloan Kettering Rockville Centre, Rockville Centre

11725

Memorial Sloan Kettering Commack, Commack

07920

Memoral Sloan Kettering Basking Ridge, Basking Ridge

07748

Memoral Sloan Kettering Monmouth, Middletown

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT03326973 - Long-Term Quality of Life in Patients With Metastatic Melanoma Treated With Checkpoint Inhibitors | Biotech Hunter | Biotech Hunter